Record Nr.	UNINA9910337531603321
Titolo	Targeted Therapies for Lung Cancer / / edited by Ravi Salgia
Pubbl/distr/stampa	Cham:,: Springer International Publishing:,: Imprint: Springer,, 2019
ISBN	9783030178314 9783030178321 (e-book)
Edizione	[1st ed. 2019.]
Descrizione fisica	1 online resource (IX, 238 p. 19 illus. in color.)
Collana	Current Cancer Research, , 2199-2584
Disciplina	614.5999 616.9942406
Soggetti	Cancer research Molecular biology Cancer Research Molecular Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	1. EGFR 2. ALK 3. ROS1 4. B-RAF 5. MET 6. HER2 7. NTRK 8. SCLC 9. Complexities of the Lung Tumor Microenvironment 10. KRAS 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.
Sommario/riassunto	This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific

indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.